Asian neTwork for Translational Research and Cardiovascular Trials ("ATTRaCT")
NCT ID: NCT02791009
Last Updated: 2024-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
815 participants
OBSERVATIONAL
2015-08-31
2021-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Evaluation of Asians With CRT for Heart Failure
NCT02814942
Singapore Cardiac Longitudinal Outcomes Database
NCT03760705
"TARGET 2.0 Study": Safety and Performance of the Cardiovalve TR Replacement System
NCT07334691
Multi- Level and Integrated Analysis of Mechanisms Underlying Atrial Dysfunction
NCT02789943
In-depth Characterization of Atriogenic Secondary Tricuspid Regurgitation Due to Atrial Fibrillation
NCT05749107
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators overall aim is to build on Singapore's competitive advantages in advanced cardiac imaging, genetic and molecular studies to develop an integrated "one -stop" platform spanning from human to large and small animal models, dedicated to deepening the understanding of CV disease progression, discovery of new targets and repurposing of drugs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnosed Heart Failure [Prior]
Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
Cardiovascular Magnetic Resonance Imaging (CMRI)
CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Electrocardiogram (ECG)
ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Blood Sample Collection
Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
Clinical Assessment
Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
Cardiovascular Ultrasound (CVUS)
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
Control [Prior]
Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
Cardiovascular Magnetic Resonance Imaging (CMRI)
CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Electrocardiogram (ECG)
ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Blood Sample Collection
Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
Clinical Assessment
Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
Cardiovascular Ultrasound (CVUS)
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
Control [New]
Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
Cardiovascular Magnetic Resonance Imaging (CMRI)
CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Electrocardiogram (ECG)
ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Blood Sample Collection
Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
Clinical Assessment
Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
Cardiovascular Ultrasound (CVUS)
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
Diagnosed Heart Failure [New]
Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection, Cognitive Test and Clinical Assessment.
Cardiovascular Magnetic Resonance Imaging (CMRI)
CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Electrocardiogram (ECG)
ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Blood Sample Collection
Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
Clinical Assessment
Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
Cardiovascular Ultrasound (CVUS)
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
Cognitive Test
To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiovascular Magnetic Resonance Imaging (CMRI)
CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Electrocardiogram (ECG)
ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
Blood Sample Collection
Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
Clinical Assessment
Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
Cardiovascular Ultrasound (CVUS)
To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
Cognitive Test
To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Present to hospital with diagnosis of HF, or
Attending a hospital clinic for management of HF within 6/12 of an episode of decompensated heart failure\* which either:
* Resulted in a hospital admission (primary diagnosis) or
* Was treated in out-patient clinic \* Appropriate symptoms and signs of HF, confirmed by PI when necessary
Exclusion Criteria
2. The primary diagnosis is an Acute coronary syndrome (ACS) which has resulted in a transient episode of Acute pulmonary oedema (APO) (Note: Patients with a troponin rise noted during the index admission, but in whom the main presentation is considered clinically to the HF will be included)
3. End stage renal failure (eGFR \< 15ml/min/m2) or is receiving or planned to receive renal replacement therapy.
4. Other specific subgroups of HF (Including constrictive pericarditis, complex adult congenital heart disease, hypertrophic cardiomyopathy, eosinophilic myocarditis, cardiac amyloid and acute chemotherapy-induces cardiomyopathy)
5. Isolated right heart failure\*\* (combined right and left heart failure will be included). (Secondary to severe lung disease or pulmonary hypertension)
6. Life threatening co-morbidity with a life expectancy of \< 1 year
7. Inability to provide informed consent
8. The patient is unable to comply with study protocol requirements
9. The patient is participating in another clinical research trial(only if that study precludes involvement in an observational study)
10. The patient has declined to participate
21 Years
99 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Singapore General Hospital
OTHER
National University Hospital, Singapore
OTHER
Tan Tock Seng Hospital
OTHER
Khoo Teck Puat Hospital
OTHER
Changi General Hospital
OTHER
National Heart Centre Singapore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carolyn Lam, MBBS
Role: PRINCIPAL_INVESTIGATOR
National Heart Centre Singapore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Heart Centre Singapore
Singapore, , Singapore
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015/2194
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.